SCYNEXIS

SCYNEXIS

  • PO Box 12878 Research Triangle Park
  • Durham, North Carolina
  • 27709

Website Links

Description

Pamela J. Kirby, Ph.D. – Chairman of the Board Dr. Kirby has served as the Chairman of our board of directors since January 2006 and has served as a director since December 2004. She brings over 25 years of experience in the pharmaceutical and biotechnology industries. Dr. Kirby served as a director of Novo Nordisk A/S, a global healthcare company, from 2008 to 2011 and as a member of the board of Simmons & Simmons LLP, an international law firm, from 2011 to 2013.

SCYNEXIS, Inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. Our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. We plan to leverage this expertise in human and animal drug development to pursue the development of our proprietary compounds.

Integrity: We will treat all employees with respect and will ethically conduct all our business activities. Innovation: We will continuously generate creative solutions to business challenges. We believe all employees can transform new thoughts and ideas into value for the company. Quality: We will deliver superior products and services that exceed our customers’ expectations. Teamwork: We value employees working together to achieve the company’s goals. Safety: We have the highest regard for the safety of our employees, customers, the public and the environment.

SCYNEXIS is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as a novel oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. In addition, we have clinical and preclinical programs based on the use of cyclophilin inhibitors to treat viral diseases, as well as contract research and development services primarily in the field of animal health. www.scynexis.com .

Fact sheet

Number of employees
110
Annual revenue
$21200000

Company contacts

  • Yves Ribeill
  • CEO

Products & services

Similar companies nearby